Citigroup’s LB Pharmaceuticals LBRX Stock Holding History

Citigroup’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$137K	Buy	5,569 +5,134	+1,180%	+$118K	﹤0.01%	4164
2025 Q4	$9.68K	Buy	+435	New	+$7.6K	﹤0.01%	5068

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citigroup's LBRX Position: Q1 2026 in Review

Citigroup increased its LB Pharmaceuticals (LBRX) stake by 1,180% in Q1 2026, buying an estimated $118K and bringing the position to 5,569 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #4164.

Citigroup first reported a position in LBRX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Citigroup held 5,569 shares of LB Pharmaceuticals worth $137K as of Q1 2026.
Citigroup bought 5,134 LB Pharmaceuticals shares in Q1 2026, an estimated $118K.
LB Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4164 holding.
Citigroup first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.